A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

MLA

Leal, Lorna, et al. “A Randomized Clinical Trial Comparing Ritonavir-Boosted Lopinavir versus Raltegravir Each with Tenofovir plus Emtricitabine for Post-Exposure Prophylaxis for HIV Infection.” The Journal of Antimicrobial Chemotherapy, vol. 71, no. 7, July 2016, pp. 1987–93. EBSCOhost, https://doi.org/10.1093/jac/dkw049.

APA

Leal, L., León, A., Torres, B., Inciarte, A., Lucero, C., Mallolas, J., Laguno, M., Martínez-Rebollar, M., González-Cordón, A., Manzardo, C., Rojas, J., Pich, J., Arnaiz, J. A., Gatell, J. M., & García, F. (2016). A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. The Journal of Antimicrobial Chemotherapy, 71(7), 1987–1993. https://doi.org/10.1093/jac/dkw049

Chicago

Leal, Lorna, Agathe León, Berta Torres, Alexy Inciarte, Constanza Lucero, Josep Mallolas, Montserrat Laguno, et al. 2016. “A Randomized Clinical Trial Comparing Ritonavir-Boosted Lopinavir versus Raltegravir Each with Tenofovir plus Emtricitabine for Post-Exposure Prophylaxis for HIV Infection.” The Journal of Antimicrobial Chemotherapy 71 (7): 1987–93. doi:10.1093/jac/dkw049.